Mont-Saint-Guibert, Belgium, September 25, 2023, 10:01 p.m. CET – regulated information – Celyad Oncology SA (Euronext: CYAD) (“Celyad Oncology” or the “Company”) announces today that Citibank, NA, as depositary (“Citibank”), will issue notice of termination of its American Depository Receipt program (“ADR Program”) of American Depositary Shares representing ordinary shares (“ADSs”) to holders of ADSs in accordance with the provisions of the agreement deposit. The ADR Program and the deposit agreement will terminate on October 26, 2023 (the “Termination Date”).
Prior to termination of the Deposit Agreement, holders of ADSs have the right to surrender their ADSs to Citibank for cancellation in accordance with the terms of the Deposit Agreement, and receive the underlying common shares of the Company. Holders of ADSs should contact Citibank or, to the extent holders hold ADSs through a bank, broker-dealer or other nominee, such holders should contact such bank, broker-dealer or this nominee for any questions regarding ADSs.